Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Choroidal Neovascularization Market Forecast: What Market Value Is Expected By 2030?
The market for choroidal neovascularization has experienced robust expansion recently, projected to advance from $4.18 billion in 2025 to $4.5 billion in 2026, demonstrating a compound annual growth rate of 7.7%. This expansion during the preceding period was driven by several key factors, including a heightened incidence of age-related macular degeneration, an increase in cases of diabetic eye disease, the proliferation of ophthalmology clinics, the accessibility of anti-angiogenic therapies, and advancements in the ability to diagnose retinal conditions.
The market for treating choroidal neovascularization is poised for significant expansion in the coming years, projected to reach $5.99 billion by 2030 with a compound annual growth rate of 7.4%. This upward trajectory during the forecast period is underpinned by several key factors, including a growing elderly demographic, a heightened emphasis on timely ophthalmic interventions, the proliferation of combined treatment strategies, increased funding for researching retinal diseases, and a greater uptake of customized treatment plans. Emerging trends within this timeframe are expected to include a wider application of anti-VEGF therapies, more frequent utilization of treat-and-extend regimens, a surge in demand for early diagnosis of CNV, advancements in retinal imaging technologies, and a concentrated effort on therapies aimed at preserving vision.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp
Choroidal Neovascularization Market Expansion Supported By Key Demand Factors
The expanding incidence of age-related macular degeneration (AMD) is anticipated to be a significant catalyst for the expansion of the choroidal neovascularization (CNV) market. AMD, a condition impacting vision primarily in older demographics, involves the progressive deterioration of the macula and results in a loss of central sight. This escalating prevalence is linked to an aging global populace, extended lifespans, shifts in lifestyle habits, genetic predispositions, and heightened susceptibility to environmental hazards. Choroidal neovascularization plays a crucial role in supporting AMD patients by facilitating the progression of the “wet” form of the disease, characterized by the formation of aberrant blood vessels under the retina, which leads to worsening vision. Effective management of CNV and mitigation of AMD progression, essential for preserving central vision, frequently necessitates sophisticated interventions like anti-VEGF treatments. Illustratively, the UHN Foundation, Canada’s official fundraising entity, identified AMD as the leading contributor to severe, permanent vision impairment in individuals exceeding 50 years of age as of 2025. With more than 200 million individuals currently affected worldwide, this figure is forecasted to reach 288 million by 2040, thereby underscoring how the growing burden of age-related macular degeneration directly fuels the expansion of the choroidal neovascularization market.
#Choroidal Neovascularization Market Segment Landscape And Growth Potential
The choroidal neovascularization market covered in this report is segmented –
1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium
2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications
3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral
4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers
Subsegments:
1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium
2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy
3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT
4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF
5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen
6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections
7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen
8) By Pegaptanib Sodium: Monotherapy, Combination Therapy
Choroidal Neovascularization Market Growth Trends Influencing Competitive Dynamics
Within the choroidal neovascularization sector, leading enterprises are dedicated to pioneering advanced treatments, including photodynamic therapy, aiming to equip eye care practitioners with accurate and effective interventions that enhance patient results and the administration of care. Photodynamic therapy (PDT) involves a medical procedure employing a light-activated photosensitizing substance to selectively eliminate aberrant or malignant cells. To illustrate, in February of 2023, Bausch & Lomb, a healthcare entity based in Canada, in conjunction with Modulight, a Finnish biomedical firm, revealed the FDA clearance of their ML6710i photodynamic laser system. This therapeutic approach has received approval for utilization alongside Bausch + Lomb’s established VISUDYNE therapy, specifically formulated for combating choroidal neovascularization associated with age-related macular degeneration (AMD). The cutting-edge, portable ophthalmic laser provides a focused method for addressing the proliferation of abnormal blood vessels within the eye, thereby contributing to the prevention of disease advancement and the safeguarding of visual acuity.
Choroidal Neovascularization Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the choroidal neovascularization market are Roche Holding AG, Regeneron Pharmaceuticals Incorporated, Bayer Aktiengesellschaft, Novartis AG, Apellis Pharmaceuticals Incorporated, Kodiak Sciences Incorporated, Adverum Biotechnologies Incorporated, Clearside Biomedical Incorporated, Graybug Vision Incorporated, Outlook Therapeutics Incorporated, Oxurion NV, 4D Molecular Therapeutics Incorporated, Opthea Limited, Eyepoint Pharmaceuticals Incorporated, Ocular Therapeutix Incorporated, OcuTerra Therapeutics Incorporated, Ocuphire Pharma Incorporated, Kubota Vision Incorporated, Amgen Incorporated, Coherus BioSciences Incorporated, Formycon AG, Alimera Sciences Incorporated, Neurotech Pharmaceuticals Incorporated, Alkeus Pharmaceuticals Incorporated, Aerie Pharmaceuticals Incorporated, Acucela Incorporated
Access The Complete Choroidal Neovascularization Market Report:
https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report
Choroidal Neovascularization Market Leading Geography: Which Region Generates The Most Revenue?
North Americawas the largest region in the choroidal neovascularization market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model